Immunocytochemical markers in stage I lung cancer

Relevance to prognosis

Ugo Pastorino, Salvatore Andreola, Elda Tagliabue, Francesco Pezzella, Matteo Incarbone, Gabriella Sozzi, Marc Buyse, Sylvie Menard, Marco Pierotti, Franco Rilke

Research output: Contribution to journalArticle

277 Citations (Scopus)

Abstract

Purpose: This study investigated the frequency of the expression and prognostic significance of a panel of immunocytochemical markers in resected non-small-cell lung cancer (NSCLC). Patients and Methods: A total of 515 cases of pathologic stage I NSCLC were analyzed. The median follow-up time of surviving patients was 102 months. The following immunocytochemical markers were tested: blood group A and precursors of blood antigens; laminin receptor; c-erbB1/epidermal growth factor receptor (EGFR) and c-erbB2/Neu; BC12; p53; and angiogenesis. Kaplan Meier estimates-of survival and time to recurrence were calculated for clinical variables and biologic markers using the Cox model for multivariate analysis. Results: The pathologic tumor extension (pT) represented the most powerful prognostic factor for survival (P = .0008) and time to recurrence (P = .0007). None of the immunocytochemical markers emerged as on independent predictive factor for survival. Bc12-positive tumors showed a better time to recurrence (P= .03), but the difference lost statistical significance in the multivariate analysis. Of interest, in the group of 137 patients classified as pTINO, both EGFR expression and nonangiogenic type of vascular pattern were associated with a poorer survival (P = .02). However, data derived from subset analysis must be interpreted cautiously. Conclusion: Our findings do not support a relevant prognostic role of immunocytochemical markers in NSCLC. The evidence is not sufficient to alter clinical practice or even to restrict clinical trials of adjuvant treatments to predefined biologic subsets of patients.

Original languageEnglish
Pages (from-to)2858-2865
Number of pages8
JournalJournal of Clinical Oncology
Volume15
Issue number8
Publication statusPublished - Aug 1997

Fingerprint

Lung Neoplasms
Non-Small Cell Lung Carcinoma
Survival
Epidermal Growth Factor Receptor
Recurrence
Multivariate Analysis
Biomarkers
Laminin Receptors
Kaplan-Meier Estimate
Blood Group Antigens
Proportional Hazards Models
Blood Vessels
Neoplasms
Clinical Trials
Antigens
Therapeutics

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

Immunocytochemical markers in stage I lung cancer : Relevance to prognosis. / Pastorino, Ugo; Andreola, Salvatore; Tagliabue, Elda; Pezzella, Francesco; Incarbone, Matteo; Sozzi, Gabriella; Buyse, Marc; Menard, Sylvie; Pierotti, Marco; Rilke, Franco.

In: Journal of Clinical Oncology, Vol. 15, No. 8, 08.1997, p. 2858-2865.

Research output: Contribution to journalArticle

Pastorino, U, Andreola, S, Tagliabue, E, Pezzella, F, Incarbone, M, Sozzi, G, Buyse, M, Menard, S, Pierotti, M & Rilke, F 1997, 'Immunocytochemical markers in stage I lung cancer: Relevance to prognosis', Journal of Clinical Oncology, vol. 15, no. 8, pp. 2858-2865.
Pastorino, Ugo ; Andreola, Salvatore ; Tagliabue, Elda ; Pezzella, Francesco ; Incarbone, Matteo ; Sozzi, Gabriella ; Buyse, Marc ; Menard, Sylvie ; Pierotti, Marco ; Rilke, Franco. / Immunocytochemical markers in stage I lung cancer : Relevance to prognosis. In: Journal of Clinical Oncology. 1997 ; Vol. 15, No. 8. pp. 2858-2865.
@article{c3e594685d174666a622d2636dabb223,
title = "Immunocytochemical markers in stage I lung cancer: Relevance to prognosis",
abstract = "Purpose: This study investigated the frequency of the expression and prognostic significance of a panel of immunocytochemical markers in resected non-small-cell lung cancer (NSCLC). Patients and Methods: A total of 515 cases of pathologic stage I NSCLC were analyzed. The median follow-up time of surviving patients was 102 months. The following immunocytochemical markers were tested: blood group A and precursors of blood antigens; laminin receptor; c-erbB1/epidermal growth factor receptor (EGFR) and c-erbB2/Neu; BC12; p53; and angiogenesis. Kaplan Meier estimates-of survival and time to recurrence were calculated for clinical variables and biologic markers using the Cox model for multivariate analysis. Results: The pathologic tumor extension (pT) represented the most powerful prognostic factor for survival (P = .0008) and time to recurrence (P = .0007). None of the immunocytochemical markers emerged as on independent predictive factor for survival. Bc12-positive tumors showed a better time to recurrence (P= .03), but the difference lost statistical significance in the multivariate analysis. Of interest, in the group of 137 patients classified as pTINO, both EGFR expression and nonangiogenic type of vascular pattern were associated with a poorer survival (P = .02). However, data derived from subset analysis must be interpreted cautiously. Conclusion: Our findings do not support a relevant prognostic role of immunocytochemical markers in NSCLC. The evidence is not sufficient to alter clinical practice or even to restrict clinical trials of adjuvant treatments to predefined biologic subsets of patients.",
author = "Ugo Pastorino and Salvatore Andreola and Elda Tagliabue and Francesco Pezzella and Matteo Incarbone and Gabriella Sozzi and Marc Buyse and Sylvie Menard and Marco Pierotti and Franco Rilke",
year = "1997",
month = "8",
language = "English",
volume = "15",
pages = "2858--2865",
journal = "Journal of Clinical Oncology",
issn = "0732-183X",
publisher = "American Society of Clinical Oncology",
number = "8",

}

TY - JOUR

T1 - Immunocytochemical markers in stage I lung cancer

T2 - Relevance to prognosis

AU - Pastorino, Ugo

AU - Andreola, Salvatore

AU - Tagliabue, Elda

AU - Pezzella, Francesco

AU - Incarbone, Matteo

AU - Sozzi, Gabriella

AU - Buyse, Marc

AU - Menard, Sylvie

AU - Pierotti, Marco

AU - Rilke, Franco

PY - 1997/8

Y1 - 1997/8

N2 - Purpose: This study investigated the frequency of the expression and prognostic significance of a panel of immunocytochemical markers in resected non-small-cell lung cancer (NSCLC). Patients and Methods: A total of 515 cases of pathologic stage I NSCLC were analyzed. The median follow-up time of surviving patients was 102 months. The following immunocytochemical markers were tested: blood group A and precursors of blood antigens; laminin receptor; c-erbB1/epidermal growth factor receptor (EGFR) and c-erbB2/Neu; BC12; p53; and angiogenesis. Kaplan Meier estimates-of survival and time to recurrence were calculated for clinical variables and biologic markers using the Cox model for multivariate analysis. Results: The pathologic tumor extension (pT) represented the most powerful prognostic factor for survival (P = .0008) and time to recurrence (P = .0007). None of the immunocytochemical markers emerged as on independent predictive factor for survival. Bc12-positive tumors showed a better time to recurrence (P= .03), but the difference lost statistical significance in the multivariate analysis. Of interest, in the group of 137 patients classified as pTINO, both EGFR expression and nonangiogenic type of vascular pattern were associated with a poorer survival (P = .02). However, data derived from subset analysis must be interpreted cautiously. Conclusion: Our findings do not support a relevant prognostic role of immunocytochemical markers in NSCLC. The evidence is not sufficient to alter clinical practice or even to restrict clinical trials of adjuvant treatments to predefined biologic subsets of patients.

AB - Purpose: This study investigated the frequency of the expression and prognostic significance of a panel of immunocytochemical markers in resected non-small-cell lung cancer (NSCLC). Patients and Methods: A total of 515 cases of pathologic stage I NSCLC were analyzed. The median follow-up time of surviving patients was 102 months. The following immunocytochemical markers were tested: blood group A and precursors of blood antigens; laminin receptor; c-erbB1/epidermal growth factor receptor (EGFR) and c-erbB2/Neu; BC12; p53; and angiogenesis. Kaplan Meier estimates-of survival and time to recurrence were calculated for clinical variables and biologic markers using the Cox model for multivariate analysis. Results: The pathologic tumor extension (pT) represented the most powerful prognostic factor for survival (P = .0008) and time to recurrence (P = .0007). None of the immunocytochemical markers emerged as on independent predictive factor for survival. Bc12-positive tumors showed a better time to recurrence (P= .03), but the difference lost statistical significance in the multivariate analysis. Of interest, in the group of 137 patients classified as pTINO, both EGFR expression and nonangiogenic type of vascular pattern were associated with a poorer survival (P = .02). However, data derived from subset analysis must be interpreted cautiously. Conclusion: Our findings do not support a relevant prognostic role of immunocytochemical markers in NSCLC. The evidence is not sufficient to alter clinical practice or even to restrict clinical trials of adjuvant treatments to predefined biologic subsets of patients.

UR - http://www.scopus.com/inward/record.url?scp=17444442088&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=17444442088&partnerID=8YFLogxK

M3 - Article

VL - 15

SP - 2858

EP - 2865

JO - Journal of Clinical Oncology

JF - Journal of Clinical Oncology

SN - 0732-183X

IS - 8

ER -